H.C. Wainwright starts coverage of Galectin Therapeutics with 'buy'

Galectin Therapeutics

17/06/2025 16:03

** H.C. Wainwright initiates coverage of drug developer Galectin Therapeutics GALT.O with 'buy' rating; sets PT at $6, which is ~233.3% upside on stock's last close

** Brokerage says Galectin is currently developing belapectin to treat chronic liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis, liver failure and liver cancer

** H.C. Wainwright says GALT's belapectin is only therapy in development for MASH cirrhosis

** "Initial clinical trials exhibited compelling trends towards preventing and halting signs and symptoms of the disease," brokerage says

** Including session's moves, stock up ~45% YTD

 (Reporting by Prakhar Srivastava in Bengaluru)

 ((Prakhar.srivastava2@thomsonreuters.com))